Abstract:The fibrillation and deposition of amyloid-β (Aβ) peptides in human brains are pathologically linked to Alzheimer's disease (AD). Development of different inhibitors (peptides, organic molecules, and nanoparticles) to prevent Aβ aggregation becomes a promising therapeutic strategy for AD treatment. We recently propose a "like-interacts-like" design principle to computationally design/screen and experimentally validate a new set of hexapeptide inhibitors with completely different sequences from the Aβ sequence. These hexapeptide inhibitors inhibit Aβ aggregation and reduce Aβ-induced cytotoxicity. However, inhibitory mechanisms of these hexapeptides and the underlying interactions between hexapeptides and Aβ remain unclear. Herein we apply multi-scale computational methods (quantum-chemical calculations, molecular docking and explicit-solvent molecular dynamic simulation) to explore the structure, dynamics, and interaction between 3 identified hexapeptides (CTLWWG, GTVWWG, and CTIYWG) and different Aβ-derived fragments and an Aβ17-42 pentamer. When interacting with 6 Aβ-derived fragments, 3 hexapeptide inhibitors show stronger interactions with two lysine-included fragments (16KLVFFA21 and 27NKGAII33) than other fragments, indicating different sequence-specific interactions with Aβ. When interacting with the Aβ17-42 pentamer, the 3 peptides show similar binding modes and interaction mechanisms by preferentially binding to the edge of the Aβ17-42 pentamer to potentially block the Aβ elongation pathway. This work provides structural-based binding information on further modification and optimization of these peptide inhibitors to experimentally enhance their inhibitory abilities against Aβ aggregation.

Self-assembly of N-terminal Alzheimer’s Β-Amyloid and Its Inhibition

Tuning Self-Assembled Morphology of the Aβ(16-22) Peptide by Substitution of Phenylalanine Residues.

Self-assembly of Short Aβ(16-22) Peptides: Effect of Terminal Capping and the Role of Electrostatic Interaction.

Energy Landscapes of the Monomer and Dimer of the Alzheimer’s Peptide Aβ(1–28)

Self-Assembling ABETA(30-36) Peptides: A Combined All-Atom and Coarse-Grained Simulation Study

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Tuning the Structure of Monomeric Amyloid Beta Peptide by the Curvature of Carbon Nanotubes

Probing aromatic, hydrophobic, and steric effects on the self-assembly of an amyloid-β fragment peptide

A Computational Study of Self-Assembled Hexapeptide Inhibitors Against Amyloid-Β (aβ) Aggregation.

Polymorphism in Alzheimer Aβ Amyloid Organization: Insight into Aβ Aggregation

Aβ(1–42) Fibril Structure Illuminates Self-Recognition and Replication of Amyloid in Alzheimer's Disease

Induced Beta-Barrel Formation of the Alzheimer'S A Beta 25-35 Oligomers on Carbon Nanotube Surfaces: Implication for Amyloid Fibril Inhibition

Self-Assembly and Neurotoxicity of β-Amyloid (21-40) Peptide Fragment: The Regulatory Role of GxxxG Motifs

Turning the structure of the A beta(42) peptide by different functionalized carbon nanotubes: a molecular dynamics simulation study

Hierarchical Self-Assembly of a Β-Amyloid Peptide Derivative.

N-terminal Domain of Amyloid-β Impacts Fibrillation and Neurotoxicity

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation

Dissecting the Behaviour of Β‐amyloid Peptide Variants During Oligomerization and Fibrillation

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease